Glatiramer acetate liposomal - Pharmsynthez/Xenetic Biosciences

Drug Profile

Glatiramer acetate liposomal - Pharmsynthez/Xenetic Biosciences

Alternative Names: Liposomal multiple sclerosis vaccine - Pharmsynthez; MyeloXen

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmsynthez
  • Developer Pharmsynthez; Xenetic Biosciences
  • Class Peptides; Polymers
  • Mechanism of Action Immunomodulators; MHC class II gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 27 Mar 2017 Xenetic Biosciences has patent protection for PolyXen™ platform technology in Europe, Asia and North America, including USA
  • 12 Feb 2016 Discontinued - Preclinical for Multiple sclerosis in Israel (SC)
  • 21 Nov 2014 Pharmsynthez completes dosing in a phase II trial in Multiple sclerosis (Second-line therapy or greater) in Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top